A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease

Matthew S Davids,Christine E Ryan,Benjamin L Lampson,Yue Ren,Svitlana Tyekucheva,Stacey M Fernandes,Jennifer L Crombie,Austin I Kim,Matthew Weinstock,Josie Montegaard,Heather A Walker,Claire Greenman,Victoria Patterson,Caron A Jacobson,Ann S LaCasce,Philippe Armand,David C Fisher,Steve Lo,Adam J Olszewski,Jon E Arnason,Inhye E Ahn,Jennifer R Brown

DOI: https://doi.org/10.1200/JCO-24-02503

2024-12-07

Abstract:Purpose: The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard of care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wildtype TP53; however, due to the chemoimmunotherapy control arm, AMPLIFY excluded patients with the high-risk TP53 aberration, for whom current standards of care are continuous Bruton tyrosine kinase inhibitor therapy or alternatively fixed-duration venetoclax-based doublets. AVO has not previously been evaluated in patients with CLL with TP53 aberration. Patients and methods: This investigator-sponsored, multicenter, phase 2 study enrolled patients with treatment-naïve CLL enriched for high-risk CLL, defined by TP53 aberration (NCT03580928). Patients received acalabrutinib, obinutuzumab, and then venetoclax, with each treatment introduced sequentially and in combination, with the duration guided by measurable residual disease (MRD). Patients who achieved undetectable MRD (uMRD) after either fifteen or twenty-four cycles could discontinue treatment. The primary endpoint was complete response (CR) with bone marrow uMRD (BM-uMRD) at the start of cycle 16. Results: Seventy-two patients were accrued, including 45 patients with TP53 aberration. The CR with BM-uMRD rates at the start of cycle 16 were 42% in patients with TP53 aberration and 42% in all-comers, and the BM-uMRD rates were 71% and 78%, respectively. Hematologic toxicities were mainly low-grade, and cardiovascular toxicities and bleeding complications were infrequent. After a median follow-up of 55.2 months, ten patients had progressed, including 4 with transformation, and three patients died. Four-year progression-free and overall survival for patients with or without TP53 aberration were 70%/96% and 88%/100%, respectively. Conclusions: AVO was highly active and well-tolerated in patients with previously untreated CLL with high-risk CLL, supporting its use as a new standard of care treatment option.